abstract |
The present invention relates to the use of benzylideneamino guanidines of general formula (I) as melanocortin receptor agonists or antagonist, and in particular, the use of benzylideneamino guanidines which show selectivity to the MC1 and MC4 melanocortin receptors as argonists and/or antagonists. |